The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

##STR00001##

The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.

##STR00001##

Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using MEK antagonists.

Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using MEK antagonists.

Provided herein are combination therapies for the treatment of pathological conditions, such as cancer, using MEK antagonists.

The present disclosure relates to ophthalmic compositions and methods for inducing PAX6 expression in a cells and for reducing or preventing corneal scarring, corneal neovascularization and/or corneal opacification. The disclosure also provide for ophthalmic compositions and methods for improving vision or reducing limitations on vision.

The present disclosure relates to ophthalmic compositions and methods for inducing PAX6 expression in a cells and for reducing or preventing corneal scarring, corneal neovascularization and/or corneal opacification. The disclosure also provide for ophthalmic compositions and methods for improving vision or reducing limitations on vision.

Disclosed herein are compositions and methods for topical delivery of mTOR inhibitors. In one embodiment, an anhydrous composition includes one or more mTOR inhibitors, one or more solvents, one or more gelling agents, and one or more antioxidants. Also disclosed herein are methods to treat skin disorders using such compositions.

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).